Biomarker Summit Europe 2016
05 October 2016 - 07 October 2016
The summit will address the latest developments in the biomarker arena from discovery to translation to commercialization. Presentations span across multiple disciplines and cover topics such as discovery and validation strategies, the challenges of clinical translation, novel technologies including next-generation sequencing, companion diagnostics, the health economics value of biomarkers, reimbursement environment, and perspective on cell free biomarkers for disease diagnostics. Scientific data, case studies and discussions will be facilitated by key representatives from pharma, biotech, academia and the public sector.
Abion Hotel Spreebogen Waterside Berlin, Germany
https://www.gtcbio.com/conferences/biomarker-summit-europe-overview?utm_source=Event%20Listing&utm_medium=bioeu2016&utm_campaign=overview
SAN2016
06 October 2016 - 09 October 2016
The Society of Applied Neuroscience in cooperation with the Medical School of the Aristotle University of Thessaloniki and the Department of Neurology of the Max Planck Institute for Human Cognitive and Brain Sciences, have the great pleasure to welcome you to the SAN2016 meeting, which will be held in Corfu Island, Greece.
We cordially invite everyone engaged in studies of Neuroscience, to participate in SAN2016 meeting. Apart from the highly promising scientific program, there will also be a lively social program which will give our guests the opportunity to enjoy Corfu Island.
Grecotel Corfu Imperial Exclusive Resort, Corfu, Greece
http://applied-neuroscience.org/san2016/index.php
European Pharmaceutical Market Access, Pricing and Reimbursement
10 October 2016 - 11 October 2016
SMi Group’s 22nd annual European Pharmaceutical Market Access, Pricing and Reimbursement conference returns to London from 10-11 October 2016. The conference is one of the most established in the world, focusing on the changes in pricing and reimbursement and market access.
As pharmaceutical global spending is predicted to increase by 29-32% by 2020*, the need for access to cheaper alternative medicines and technology is essential. The use of generics is on the rise and it's expected that by 2020, 88%* of total medicine use will be attributed to generics, over the counter, and non-original branded products.
Holiday Inn Kensington Forum, London, UK
https://www.smi-online.co.uk/pharmaceuticals/uk/european-pharmaceutical-pricing-reimbursement
Society for Medicines Research "Rare Diseases, Extraordinary Aspirations"
13 October 2016
Orphan drugs are designated drug substances that are intended to treat rare or ‘orphan’ diseases which are classified as less than 200,000 total individual cases in the US and a rate of <5 in 10,000 individuals in the EU. More than 7000 rare diseases are known that collectively affect some 6-7% of the developed world’s population. 75% of patients are children, a third of whom will die before they reach the age of 5 years old. In the case of cancer, all but the four most common indications fall under the orphan disease definition. Given this, the cancer community normally classifies “rare cancers” as those with an incidence of less than 6 per 100,000 persons per year. Individually any single rare disease may only affect a handful of people making them a relatively unattractive prospect for the biopharmaceutical industry to target. However, ground breaking legislation starting with the Orphan Drug Act that was passed in the US in 1983 now provides financial incentives for companies to develop orphan drugs sparking ever increasing interest from biopharmaceutical companies to tackle rare diseases.
Today, rare diseases and the drugs that treat them are sufficiently attractive that many companies and research institutes now have research units dedicated to this area of research. It is therefore timely to review the area of orphan drugs and some of the basic science, drug discovery and regulatory factors that underpin this important, and growing, area of biomedical research.
This meeting brings together experts from academia, industry and disease advocacy organisations working in the rare disease field to present their experiences and thoughts on tackling rare diseases through case studies and opinion pieces. This promises to be an exciting and interesting meeting with in depth discussion of how the drug discovery and development community has approached rare disease research in the past and how this will evolve in the future to allow broader access to rare disease therapeutics. It will provide an excellent networking environment for anyone interested in this important research area.
National Heart and Lung Institute, Dovehouse Street London SW3 6LY
https://www.smr.org.uk/SMR/Meetings/20161013/Default.asp
Drug Discovery 2016
13 October 2016 - 14 October 2016
Drug Discovery 2016 marks the 10th anniversary of our flagship meeting. We return to Liverpool for what promises to be a fantastic event. This year, we will explore innovative technologies and approaches that can be used to overcome drug development challenges, and bring together industry leaders who will discuss future opportunities for novel therapeutic discovery.
ACC Liverpool, UK
http://elrig.org/portfolio/drug-discovery-2016/
4th International Congress on Translational Medicine
17 October 2016 - 20 October 2016
USTM-2016 will discuss and showcase latest developments in specific areas of cellular & molecular biology, big data mining & omics sciences, biomarkers & molecular imaging, drug discovery & development, Precision medicine & point of care diagnostics and disease modeling. The conference will unite scientists, clinicians, world leaders and experts from research institutions, industry, regulatory agencies, policy makers, and governments.
Prague, Czech Republic
http://eutranslationalmedicine.org/eustm-2016/
Discovery Informatics & Analytics Summit 2016
19 October 2016 - 20 October 2016
Why attend Discovery Informatics & Analytics 2016?
This is the only event specifically focused on how to apply advanced informatics and analytics to unlock scientific insights at discovery phase. Transformational strategies and techniques have already been applied at the forefront of discovery informatics, and this year's event will showcase practical use cases of how to power drug discovery using these tools.
Uniting senior scientists from chemistry and biology, Discovery Informatics & Analytics 2016 offers inspirational keynote speeches, practical case studies offering immediate takeaways, interactive discussion sessions, and maximum opportunity to engage and network with colleagues from Europe and beyond.
tba London, UK
http://www.discovery-informatics.com/8/venue/53/venue-information/
COPD: Modelling Future Needs to Adopt Your Novel Therapeutics and Management Strategies
19 October 2016 - 20 October 2016
SMi proudly presents the 8th annual COPD conference in London, 2016!
This event is about the developments made in the field of COPD.
COPD accounts for a substantial number of deaths in Great Britain: it has consistently given rise to between 25,000 and 30,000 deaths each year over the last 25 years
Holiday Inn Kensington Forum, London, UK
https://www.smi-online.co.uk/pharmaceuticals/uk/copd-novel-therapeutics-and-management-strategies
5th Annual Orphan Drugs Event 2016
19 October 2016 - 20 October 2016
SMi’s 5th annual Orphan Drugs event will bring together leading industry professionals to discuss the latest regulatory developments, explore how to reduce costs and how venture capital fits in the industry, and learn from the latest innovations in the orphan drug landscape. Featured speakers include: Abeona Therapeutics, National Institute for Health and Care Excellence, Alexion Pharma, Mereo BioPharma, Cydan Development, Tikomed, INC Research and more.
IN ADDITION, TWO PRE-CONFERENCE WORKSHOPS:
• Planning for success: Developing the optimal orphan drug development strategy
Hosted by: Cell Medica & Chiesi Farmaceuitci
• Paving the way for achieving orphan drug market access
Hosted by RJW & Partners
Holiday Inn Kensington Forum, London, UK
http://www.orphandrugs-event.com/ddt
2nd Antibody Drug Conjugates Conference
24 October 2016 - 25 October 2016
We invite you to attend the 2nd Antibody Drug Conjugates Conference, which will take place October 24-25, 2016 in Boston, MA. This event will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain a fresh perspective on the emergence of recent data from ADC clinical trials, new linkers and payloads, personalized healthcare, site specific attachment, and ADC therapeutics.
With the field of antibody drug conjugates rapidly expanding and the increasing number of ADC clinical trials, novel therapeutics are emerging. The ADC therapeutic area combines synthetic chemistry with rationale biology and is advancing monoclonal antibody treatments into the realm of precision medicine with improved effectiveness and therapeutic indices.
Hyatt Regency, Boston, MA, USA
https://www.gtcbio.com/conferences/antibody-protein-therapeutics-overview
4th Antibody & Protein Therapeutics Conference
25 October 2016 - 26 October 2016
We welcome you to the 4th Antibody & Protein Therapeutics Conference, which will be held October 25-26, 2016 in Boston, MA. This conference strives to connect industry and academic researchers in the protein therapeutics field to facilitate discussion on the current state of the industry and discuss recent studies and challenges involved in therapeutic development.
Representatives from big pharma, academic institutions and government research labs will present data and case studies on key topics including antibody drug conjugates, bispecific antibodies, antibody combinations, and check point inhibiting antibodies. Attend to learn and network with key opinion leaders in a highly interactive and intimate environment.
Hyatt Regency, Boston, MA, USA
https://www.gtcbio.com/conferences/antibody-protein-therapeutics-overview
Emerging Paradigms in Drug Discovery & Chemical Biology
25 October 2016
Chemical Biology is changing the face of drug discovery. Over the past decade, chemistry based approaches have facilitated unprecedented advances in our understanding of cell biology and animal physiology, and have proven highly useful for drug discovery, demonstrating success not only in target and mechanism identification, but also in target validation and off-target identification. This symposium will highlight recent advances in on-target and off-target identification of drug-protein interactions in physiologically relevant systems, and will feature talks on the ubiquitin proteasome system, GPCRs, protein lipidation mechanisms, neurobiology, and cancer.
The New York Academy of Sciences
http://www.nyas.org/Events/Detail.aspx?cid=79818d7a-47bf-467c-bcdb-36e550207258
4th Protein-Protein Interaction Conference
25 October 2016 - 26 October 2016
The relatively new field of protein-protein interaction (PPI) is experiencing a fantastic growth in the field of drug discovery. The key concepts of PPI are to understand how proteins interact, why inhibiting protein-protein interaction is beneficial, and how to identify molecules that block the protein-protein interactions so that treatment strategies can be formulated.
GTCbio's upcoming 4th Protein-Protein Interaction Conference is to be held on October 25-26, 2016 in Boston, MA. This conference will have sessions that cover novel techniques, new algorithms and databases for PPIs, and potential druggable sites for disrupting protein-protein interactions. Attendees will gain an enhanced understanding of the molecular basis and inhibitor design of peptide and protein aggregation. In addition, attendees will obtain insights into the latest use of PPIs in the area of cancer research. Join this multi-disciplinary forum and network with colleagues from industry and academia to discuss the methods and tools that will ensure the most efficient and accurate optimization of protein-protein interaction.
Hyatt Regency, Boston, MA, USA
https://www.gtcbio.com/conferences/protein-protein-interaction-overview?utm_source=Event%20Listing&utm_medium=4ppi&utm_campaign=overview
8th Annual PEGS Europe
31 October 2016 - 04 November 2016
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. Over the last three years, participation at PEGS Europe has grown by more than 60%, and this year will be the largest ever. With a more-focused technical program, and double the coverage of the most popular PEGS topics, the 2016 event will feature:
700 attendees
200 technical presentations
125 scientific posters
Dedicated networking opportunities
Exclusive exhibit & poster viewing hours
Interactive roundtable, breakout & panel discussions
EPIC SANA Lisboa Hotel, Lisbon, Portugal
http://www.pegsummiteurope.com/